Mitoxantrone in progressive multiple sclerosis: A placebo controlled, randomized, observer blind phase III trial: Clinical results and three-year follow-up

被引：0
|
作者：
Hartung, HP
Gonsette, R
机构：
来源：
NEUROLOGY | 1999年 / 52卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：A290 / A290
页数：1
相关论文
共 50 条
  • [41] Long-term effectiveness of two models of brief psychotherapy for depression: A three-year follow-up randomized clinical trial
    dos Santos, Erico Nobre
    Molina, Mariane Lopez
    Mondin, Thaise
    Cardoso, Taiane de Azevedo
    Silva, Ricardo
    Souza, Luciano
    Jansen, Karen
    PSYCHIATRY RESEARCH, 2020, 286
  • [42] THE NATURAL HISTORY OF NOCTURIA AMONG MEN ALLOCATED TO PLACEBO: RESULTS FROM A RANDOMIZED CONTROLLED TRIAL WITH ONE YEAR FOLLOW-UP
    Tikkinen, Kari A. O.
    Haukka, Jari
    Cartwright, Rufus
    Vaughan, Camille P.
    Markland, Alayne D.
    Howard, Marion Ellen
    Jones, Karen M.
    Goode, Patricia S.
    Burgio, Kathryn L.
    Johnson, Theodore M.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E502 - E503
  • [43] Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine
    Rossini, PM
    Pasqualetti, P
    Pozzilli, C
    Grasso, MG
    Millefiorini, E
    Graceffa, A
    Carlesimo, GA
    Zibellini, G
    Caltagirone, C
    MULTIPLE SCLEROSIS, 2001, 7 (06): : 354 - 358
  • [44] Efficacy and safety of rituximab in patients with primary progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, multicenter trial
    Hawker, Kathleen S.
    O'Connor, Paul
    Freedman, Mark S.
    Calabresi, Peter A.
    Antel, Jack P.
    Simon, Jack
    Hauser, Stephen L.
    Waubant, Emmanuelle
    Vollmer, Timothy
    Panitch, Hillel
    Zhang, Jiameng
    Chin, Peter
    Smith, Craig
    MULTIPLE SCLEROSIS, 2008, 14 : S299 - S299
  • [45] Efficacy and safety of siponimod in secondary progressive multiple sclerosis - Results of the placebo controlled, double-blind, Phase III EXPAND study.
    Kappos, L.
    Bar-Or, A.
    Cree, B.
    Fox, R.
    Giovannoni, G.
    Gold, R.
    Vermersch, P.
    Arnould, S.
    Sidorenko, T.
    Wolf, C.
    Wallstroem, E.
    Dahlke, F.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 828 - 829
  • [46] Efficacy and Safety of Ocrelizumab in Primary Progressive Multiple Sclerosis: Results of the Phase III Double-Blind, Placebo-Controlled ORATORIO Study
    Montalban, Xavier
    Hemmer, Bernhard
    Rammohan, Kottil
    Giovannoni, Gavin
    De Seze, Jerome
    Bar-Or, Amit
    Arnold, Douglas
    Sauter, Annette
    Masterman, Donna
    Fontoura, Paulo
    Garren, Hideki
    Chin, Peter
    Wolinsky, Jerry
    NEUROLOGY, 2016, 86
  • [47] Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study
    Montalban, X.
    Hemmer, B.
    Rammohan, K.
    Giovannoni, G.
    de Seze, J.
    Bar-Or, A.
    Arnold, D. L.
    Sauter, A.
    Kakarieka, A.
    Masterman, D.
    Chin, P.
    Garren, H.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 781 - 782
  • [48] Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
    McCloskey, EV
    Dunn, JA
    Kanis, JA
    MacLennan, ICM
    Drayson, MT
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1035 - 1043
  • [49] N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
    Thomas Wolfsegger
    Klaus Böck
    Wolfgang Schimetta
    Tim J. von Oertzen
    Hamid Assar
    Neurological Research and Practice, 3
  • [50] N,N-Dimethylglycine in patients with progressive multiple sclerosis: result of a pilot double-blind, placebo, controlled randomized clinical trial
    Wolfsegger, Thomas
    Boeck, Klaus
    Schimetta, Wolfgang
    von Oertzen, Tim J.
    Assar, Hamid
    NEUROLOGICAL RESEARCH AND PRACTICE, 2021, 3 (01):
12345